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Sirs:
A 31-year-old female patient from India presented to our 
institution with proteinuria. The initial screening by dipstick 
urinalysis showed a proteinuria level of 1000 mg/dL, while 
the 24-h urine collection registered 4.01 g of protein and 
602 mg of creatinine. These abnormalities were diagnosed 
during her second pregnancy and persisted for 5 months 
after delivery. Retrospectively, proteinuria was already pre-
sent during her first pregnancy 2 years before but was not 
followed up thereafter. Apart from occasional mild shoulder 
pain, the patient reported no complaints, in particular, no 
B-symptoms and Raynaud’s phenomenon was absent. The 
physical examination was unremarkable, there was no edema 
or dermatological alterations, and all peripheral pulses were 
palpable.
Due to the unclear origin of the nephrotic syndrome, a 
biopsy of the kidney was performed. The histological results 
showed vascular and glomerular AA amyloidosis, which was 
also verified by high levels of serum amyloid A (48 mg/
dl—reference value < 10 mg/dl). An echocardiogram and 
abdominal ultrasound were performed to exclude further 
organ involvement but were unremarkable.
To investigate the underlying causes of AA amyloido-
sis, we performed an extensive microbiological panel, 
which showed negative results for viruses [hepatitis B/C, 
human immunodeficiency virus (HIV), Epstein-Barr virus 
(EBV), Cytomegalovirus (CMV)], bacteria (specific tests 
for Treponema pallidum, Yersinia and mycobacteria, nega-
tive blood cultures) and parasites (Leishmania, Schistosoma, 
Cryptosporidium, Giardia, Amoeba). The diagnostic workup 
for rheumatological diseases did not reveal any anomalies, 
with normal titers of rheumatoid factor, anti-cyclic citrul-
linated peptide antibodies, anti-ds-DNA antibodies, anti-
nuclear antibodies and anti-neutrophil cytoplasmic anti-
bodies. Due to an erythrocyte sedimentation rate (ESR) of 
80 mm/h and a C-reactive protein (CRP) of 30 mg/l, the 
search for an inflammatory trigger was continued with a 
colonoscopy, which was also unremarkable. The bone mar-
row biopsy showed an infiltration of 10–15% polyclonal 
plasma cells compatible with chronic inflammation but with 
no signs of a specific diagnosis such as hemophagocytosis, 
lymphoma or leukemia.
Due to conspicuous hypochromic and microcytic anemia, 
we performed hemoglobin electrophoresis, which confirmed 
the diagnosis of beta-thalassemia minor. However, this con-
dition is not commonly associated with AA amyloidosis and 
was unlikely to be the underlying cause but rather an inci-
dental finding.
With no specific results thus far, we performed an FDG-
positron emission tomography (PET) scan, which showed 
mild inflammation of the aorta and carotid arteries (Fig. 1a, 
b). These results were indicative of large-vessel vasculitis. 
Considering the patient’s characteristics and clinical pres-
entation, the diagnosis of Takayasu arteritis (TA) was made.
Treatment with subcutaneous methotrexate 15 mg/week 
and prednisone 30 mg/day was initiated. Subcutaneous toci-
lizumab (162 mg) was added to the initial therapy, allowing 
for steroid tapering. Two weeks after the start of therapy, we 
observed a quick normalization of all inflammatory param-
eters (CRP: 0.8 mg/dL and ESR: 30 mm/h) and proteinu-
ria and an increase in serum albumin levels (from 33.5 to 
45.1 g/L). Figure 1c, d summarizes the course of CRP, ESR 
and serum albumin over time. A second renal biopsy was 
not performed.
Amyloidoses are a group of diseases characterized by the 
accumulation of pathological amyloids in different tissues 
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[1]. The most common types of amyloidoses are amyloid 
A amyloidosis (AA), light chain amyloidosis (AL), tran-
sthyretin amyloidosis (ATTR) and β2-microglobulin amy-
loidosis (Aβ2M). The symptoms are heterogeneous and 
can vary from carpal tunnel syndrome to chronic cardiac 
failure [2, 3]. The heart, kidneys, gastrointestinal tract and 
nervous system are frequently impaired, and without treat-
ment, the disease can lead to a loss of function and mortality 
[4]. The prognosis remains poor, especially in patients with 
cardiac involvement [5]; however, an early diagnosis is of 
fundamental importance, since an appropriate therapy can, 
depending on the amyloidosis type, reduce or reverse its 
progress [6, 7].
Renal involvement is the most common presentation 
of AA amyloidosis and is found in approximately 90% of 
patients. The involvement can vary from mild proteinuria 
to renal failure or nephrotic syndrome. While in develop-
ing countries, the most common cause of AA amyloidosis is 
infections, in western countries, it is commonly associated 
with autoimmune diseases [8]. Rheumatoid arthritis, juvenile 
idiopathic arthritis and ankylosing spondylitis are the most 
frequent underlying diseases associated with AA amyloido-
sis, accounting for 23–51%, 7–48% and 0–12% of all cases, 
respectively [9]. The initial suspicion that the underlying 
cause was likely to be of infectious origin was excluded after 
an extensive microbiological investigation. Therefore, we ini-
tiated a search for other inflammatory diseases that lead to the 
diagnosis of TA. Even though only one diagnostic criterion 
of the American College of Rheumatology (ACR) for TA 
was met at the time of diagnosis (age under 40 years), the 
totality of evidence was still very suggestive. Other causes 
of aortitis, such as syphilis or other acute infections, were 
ruled out using immune assays and blood cultures. Further-
more, the elevated inflammatory parameters over more than 
2 years were also suggestive of a chronic process and did not 
favor other acute infections. Although the ACR criteria are 
an important diagnostic tool, they include late features of the 
disease and thus advanced vascular involvement. Considering 
the early diagnosis in our patient, these changes had not yet 
taken place, making the diagnosis with the application of the 
ACR criteria impossible. However, FDG-PET/CT imaging 
has a strong sensitivity and specificity for the diagnosis of 
TA, and due to the highly suggestive findings in this case, 
we rely on imaging results rather than vascular symptoms 
for making the diagnosis of TA.
The association between TA and AA amyloidosis has been 
described, but due to the low incidence of both conditions, 
only a few cases are reported in the literature [8]. Table 1A 
Fig. 1  a FDG-PET CT scan showing increased metabolic activity in 
the aortic arch. b FDG-PET CT scan showing increased metabolic 
activity of the aortic wall. c Shows the values of CRP over time. d 
Shows the values of serum albumin and ESR over time. The arrows 
represents the introduction of therapy
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shows the most common causes of AA amyloidosis, while 
Table 1B shows the prevalence of TA in different countries. 
The time of the manifestation of AA amyloidosis after 
the diagnosis of the underlying disease can vary. Studies 
investigating the development of AA amyloidosis in rheuma-
tological patients have reported a median of 17–26 years of 
disease before the onset of amyloidosis. It is rather unusual 
that AA amyloidosis manifests itself as the initial symptom 
of the underlying disease [10].
The presentation of Takayasu arteritis is unspecific, and 
approximately 10% of all cases can be asymptomatic. Clini-
cal manifestations can vary from constitutional to dermato-
logical symptoms; therefore, in many patients, TA is diag-
nosed only once vascular involvement is already advanced.
Few reports have demonstrated an association between 
AA amyloidosis and Takayasu arteritis [8, 11, 12], and only 
in a few cases was AA amyloidosis the initial manifesta-
tion of TA [11, 12]. Considering the slow progression and 
sometimes long periods of subclinical disease observed in 
TA, it is reasonable to suggest that AA amyloidosis, in this 
scenario, shows a different natural history when compared 
to other diseases, such as rheumatoid arthritis, in which the 
clinical manifestations and diagnosis are present for many 
years before the onset of AA amyloidosis.
The choice of adding tocilizumab despite pending EMA 
approval has a strong rationale due to the positive effects 
of tocilizumab on both conditions. Retrospective stud-
ies and case reports have demonstrated good results with 
tocilizumab in AA amyloidosis, including the suppression 
of SAA levels and the regression of AA protein deposits 
[13]. The use of IL-6 inhibition alone in TA has also been 
demonstrated to be effective, but the evidence is still lim-
ited [14]. Furthermore, IL-6 blockade in patients with rheu-
matic diseases is associated with an improvement of vascu-
lar function [15]. Considering the severe manifestations of 
AA amyloidosis in our patient, the first goal of therapy was 
the reduction of proteinuria and the prevention of further 
renal damage. The introduction of tocilizumab in this patient 
resulted in a quick reduction of all inflammatory parameters 
and proteinuria. Considering the very early start of therapy 
in the course of vasculitis, it is reasonable to expect disease 
control with a clinically significant reduction in progression, 
preventing advanced vascular involvement.
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Table 1  a Prevalence and incidence of TA differ greatly between 
countries with the highest reported prevalence in Japan and the lowest 
in the USA. b Underlying causes for AA amyloidosis are predomin-
antely either of infectious or autoimmune origin but can also include 
malignant diseases
*This table reflects data of several epidemiological studies with dif-
ferent methods and diagnostic criteria [8]





(A) Prevalence and incidence of takayasu arteritis worldwide* [8]
 Japan 40 1–2
 United Kingdom 4.7 0.8
 Turkey 14.7–33 0.38–3.4
 Northern Europe 6.4–22 0.4–1.5
 Kuwait 7.8 2.2
 USA 0.9 2.6
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